![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Azlin
2. Azlocillin Sodium
3. Azlocillin, Sodium
4. Bay E 6905
5. Bay-e 6905
6. Baye 6905
7. Securopen
8. Sodium Azlocillin
9. Sodium, Azlocillin
1. 37091-66-0
2. Azlocilina
3. Azlocilline
4. Azlocillinum
5. Azlocilina [inn-spanish]
6. Azlocilline [inn-french]
7. Azlocillinum [inn-latin]
8. Chebi:2956
9. Azlocillin Sodium Salt
10. Hum6h389w0
11. J01ca09
12. Nsc-758227
13. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-((r)-2-(2-oxo-1-imidazolidinecarboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid
14. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
15. 37091-65-9
16. Azlocillin (usan/inn)
17. Unii-hum6h389w0
18. Azlocillin [usan:inn:ban]
19. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-(((2r)-2-(((2-oxoimidazolidin-1-yl)carbonyl)amino)-2-phenylacetyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid
20. Einecs 253-348-2
21. Azlocillin [mi]
22. Azlocillin [inn]
23. Prestwick3_000821
24. Azlocillin [usan]
25. Azlocillin [vandf]
26. Epitope Id:141185
27. 6-((r)-2-(2-oxoimidazolidin-1-carboxamido)-2-phenylacetamido)penicillansaeure
28. Azlocillin [mart.]
29. Azlocillin [who-dd]
30. Chembl1537
31. Schembl34150
32. Bspbio_000741
33. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
34. Bpbio1_000817
35. Dtxsid1022639
36. Zinc3830261
37. Akos025402328
38. Ac-8140
39. Db01061
40. Ds-3291
41. Nsc 758227
42. 2,2-dimethyl-6beta-[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]penam-3alpha-carboxylic Acid
43. 91a659
44. C06839
45. D02339
46. D81792
47. A823527
48. Q510154
49. Brd-k60663764-236-02-1
50. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-((r)-2-(2-oxoimidazolidine-1-carboxamido)-2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
51. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetamido]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
52. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid
53. (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2s)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenyl-acetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid;azlocillin
54. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3,3-dimethyl-7-oxo-6-(((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, (2s-(2.alpha.,5.alpha.,6.beta.(s*)))-
55. 4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic Acid, 3,3-dimethyl-7-oxo-6-(((((2-oxo-1-imidazolidinyl)carbonyl)amino)phenylacetyl)amino)-, (2s-(2alpha,5alpha,6beta(s*)))-
56. 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid, 3,3-dimethyl-7-oxo-6-[[[[((r)-2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, (2s,5r,6r)-
57. 4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid,3,3-dimethyl-7-oxo-6-[[[[(2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, [2s-[2a,5a,6b(s*)]]-
Molecular Weight | 461.5 g/mol |
---|---|
Molecular Formula | C20H23N5O6S |
XLogP3 | 0.1 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 5 |
Exact Mass | 461.13690464 g/mol |
Monoisotopic Mass | 461.13690464 g/mol |
Topological Polar Surface Area | 173 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 844 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of infections caused by Pseudomonas aeruginosa, Escherichia coli, and Haemophilus influenzae.
Similar to [mezlocillin] and [piperacillin], azlocillin is an acylampicillin that exhibits an extended-spectrum of activity and _in vitro_ potency that is greater than that of the carboxy penicillins. Azlocillin is shown to be effective against a broad spectrum of bacteria, including Pseudomonas aeruginosa and enterococci.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01C - Beta-lactam antibacterials, penicillins
J01CA - Penicillins with extended spectrum
J01CA09 - Azlocillin
Absorption
Not significantly absorbed from the gastrointestinal tract.
Eliminated predominantly by renal mechanisms, but also undergoes biotransformation within body tissues and intraintestinal degradation by bowel bacteria, with high concentrations found in bile.
Mean elimination half-life is 1.3 to 1.5 hours. Longer in neonates, and 2 to 6 hours in patients with renal impairment.
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, azlocillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that azlocillin interferes with an autolysin inhibitor.